908 Devices Inc. (NASDAQ:MASS) Forecasted to Earn Q1 2025 Earnings of ($0.31) Per Share

908 Devices Inc. (NASDAQ:MASS) – Stock analysts at Leerink Partnrs issued their Q1 2025 EPS estimates for shares of 908 Devices in a report issued on Tuesday, April 30th. Leerink Partnrs analyst P. Souda expects that the company will post earnings of ($0.31) per share for the quarter. The consensus estimate for 908 Devices’ current full-year earnings is ($1.27) per share. Leerink Partnrs also issued estimates for 908 Devices’ Q2 2025 earnings at ($0.28) EPS, Q3 2025 earnings at ($0.19) EPS and Q4 2025 earnings at ($0.16) EPS.

908 Devices (NASDAQ:MASS) last announced its quarterly earnings data on Tuesday, April 30th. The company reported ($0.33) earnings per share for the quarter, beating the consensus estimate of ($0.36) by $0.03. 908 Devices had a negative return on equity of 20.47% and a negative net margin of 68.57%. The firm had revenue of $9.99 million during the quarter, compared to the consensus estimate of $9.29 million. During the same quarter in the previous year, the company posted ($0.39) earnings per share. The business’s revenue was up 5.3% on a year-over-year basis.

908 Devices Stock Down 0.4 %

Shares of 908 Devices stock opened at $5.65 on Thursday. The company’s fifty day simple moving average is $6.54 and its two-hundred day simple moving average is $7.06. 908 Devices has a 12-month low of $4.85 and a 12-month high of $12.51. The firm has a market cap of $186.34 million, a PE ratio of -5.28 and a beta of 1.02.

Institutional Trading of 908 Devices

A number of institutional investors have recently modified their holdings of the company. ARK Investment Management LLC raised its position in 908 Devices by 8.3% during the 4th quarter. ARK Investment Management LLC now owns 4,346,579 shares of the company’s stock valued at $48,769,000 after purchasing an additional 333,119 shares during the last quarter. Granahan Investment Management LLC raised its holdings in shares of 908 Devices by 10.6% during the fourth quarter. Granahan Investment Management LLC now owns 2,038,658 shares of the company’s stock valued at $22,874,000 after acquiring an additional 195,368 shares in the last quarter. Iron Triangle Partners LP lifted its stake in 908 Devices by 31.1% in the fourth quarter. Iron Triangle Partners LP now owns 1,284,947 shares of the company’s stock worth $14,417,000 after acquiring an additional 304,484 shares during the period. Sumitomo Mitsui Trust Holdings Inc. boosted its holdings in 908 Devices by 3.0% in the third quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 629,994 shares of the company’s stock valued at $4,196,000 after acquiring an additional 18,492 shares in the last quarter. Finally, AWM Investment Company Inc. purchased a new position in 908 Devices during the 3rd quarter valued at $3,740,000. 88.06% of the stock is currently owned by hedge funds and other institutional investors.

About 908 Devices

908 Devices Inc, a commercial-stage technology company, provides various purpose-built handheld and desktop mass spectrometry devices to interrogate unknown and invisible materials in life sciences research, bioprocessing, pharma/biopharma, forensics, and adjacent markets. The company's products include MX908, a handheld, battery-powered, and Mass Spec device that is designed for rapid analysis of solid, liquid, vapor, and aerosol materials of unknown identity; Rebel, a small desktop analyzer that provides real-time information on the extracellular environment in bioprocesses; and Maverick, an optical in-line analyzer that offers real-time monitoring and control of multiple bioprocess parameters, including glucose, lactate, and total biomass in mammalian cell cultures, as well as provides process fingerprint data to support large-scale efforts in predictive bioprocess modeling.